You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Alpha Tau Medical Ltd. said its ordinary shares will join the TA-90 and TA-125 indices of the Tel Aviv Stock Exchange effective Nov. 5, 2026; index-tracking funds are expected to add them to their holdings.
Alpha Tau Medical Ltd. signed an MOU with Samsung Medical Center in Seoul on Oct. 22, 2026, to explore a potential Alpha DaRT clinical trial for pancreatic cancer patients in South Korea, subject to regulatory and ethics committee approvals.
Alpha Tau Medical Ltd. announced FDA approval to expand its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma from 10 to 20 patients, with new endpoints and an interim analysis, and that data will be presented at the SNO 2026 Annual Meeting on November 13.
At an October 15, 2026 DRTS conference, Alpha Tau Medical discussed AlphaDart treatment of three recurrent GBM patients, with two complete responses and one 30% reduction, no unanticipated high-grade CNS toxicities, and a pending FDA request to add seven more patients.
